RZLTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:33):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
本日の出来高	108 528
平均出来高	334 133
時価総額	106.14M
EPS	$0 ( 2024-02-09 )
次の収益日	( $-0.340 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.40
ATR14	$0.0260 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Roberts Brian Kenneth	Buy	500	Common Shares
2022-07-22	Handok, Inc.	Buy	3 157 895	Common Shares
2021-10-15	Handok, Inc.	Buy	769 231	Common Shares
2024-03-15	Evans Daron	Buy	20 000	Common Shares
2024-03-14	Roberts Brian Kenneth	Buy	10 000	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 107 305 216 \| Sell: 58 571 575

ボリューム相関

長: 0.07 (neutral)

短: 0.29 (neutral)

Signal:(44.497) Neutral

Rezolute, Inc. 相関

10 最も正の相関
SY	0.885
RNA	0.884
ANDE	0.879
PIRS	0.873
EYEN	0.872
BRACU	0.87
ZGNX	0.87
PAE	0.865
MLAC	0.865
PALT	0.865

10 最も負の相関
TRMK	-0.872
CFV	-0.866
BCYC	-0.864
AYTU	-0.851
GOOD	-0.849
GMII	-0.847
TUEM	-0.843
NAKD	-0.842
RBB	-0.837
DTSS	-0.837

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Rezolute, Inc. 相関 - 通貨/商品

0.16
( neutral )

0.20
( neutral )

0.00
( neutral )

0.25
( neutral )

0.26
( neutral )

-0.24
( neutral )

Rezolute, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2023
収益:	$0
総利益:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2022
収益:	$0
総利益:	$-256 000 (0.00 %)
EPS:	$-2.13

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.72

Financial Reports:

No articles found.

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.